RT期刊文章SR电子T1 NTM模块的初步验证：针对患有肺部无结核分枝杆菌病JF欧洲呼吸杂志的患者报告的结局指标JO EUR RESSIR J FD欧洲呼吸协会SP 1901300 DO 10.1183/13993/13993003.01300300300300300-201300-20 VO 55 IS 1 155188bet官网地址A1 Henkle，Emily A1 Winthrop，Kevin L. A1 Ranches，Gregory P. A1 Plinke，Wesley A1 Litvin，Hana K. A1 Quittner，Alexandra L. yr 2020 Ul 2020 Ul //www.qdcxjkg.com/content/content/55/1/55/1/1901300.ABSTRACT AB简介无结核分枝杆菌（NTM）引起慢性，衰弱的肺部疾病。患者报告的结果提供了症状，功能和治疗反应的措施。在这里，我们描述了最近开发的NTM模块的初步验证。研究人群包括西北NTM生物库患者，其中孤立的分枝杆菌（MAC）被分离出来，并且曾经遇到过2007年美国胸部疾病/美国胸部疾病社会的肺部疾病肺部疾病社会标准。NTM模块在入学率和12个月时进行管理；一个子集还完成了生活质量问卷调查 - 支气管扩张（QOL-B）。NTM模块产生四个领域得分（0-100；更高的分数表明功能更好），反映了NTM特异性症状（NTM症状，身体形象，消化症状和饮食问题）。我们描述了患者特征和平均得分，并评估了心理测量特性，包括每个领域的12个月治疗反应。总体上，包括203例肺MAC疾病患者。平均入学率从76（NTM症状）到84（饮食问题）不等。 Ceiling effects were observed for Body Image (26% of participants) and Eating Problems (52%). Internal consistency (Cronbach's alpha) ranged from 0.67 (Digestive Symptoms) to 0.89 (Eating Problems). The intraclass correlation for test–retest reproducibility (n=27) ranged from 0.72 (Body Image) to 0.94 (Eating Problems). Patients starting treatment (n=35) had statistically significant increases in scores for NTM Symptoms (+5, p=0.04), Digestive Symptoms (+7, p=0.002), Body Image (+7, p=0.03) and QOL-B Respiratory Symptoms (n=25, +10, p=0.006). NTM Symptoms scores increased by 15 points (p=0.002) in the 16 patients with scores ≤80 at enrolment.Conclusion The NTM Module generally performs well as a valid patient-reported outcome for pulmonary MAC disease and was responsive to MAC treatment.The NTM Symptom Module is a valid patient-reported outcome tool that can facilitate patient-centred care and may be used as an outcome in clinical trials to support labelling claims for regulatory bodies. http://bit.ly/2nwlPgi